cilostazol has been researched along with Diabetic Nephropathies in 10 studies
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated association between hyperinsulinemia/insulin resistance and microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rat." | 5.32 | Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat. ( Oshiro, Y; Shimabukuro, M; Shimajiri, Y; Takasu, N; Tohma, T; Yamakawa, M, 2004) |
| "Cilostazol was reported to lower the production of superoxide significantly in situ." | 1.36 | Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB. ( Chen, CC; Chen, HC; Lee, HJ; Lee, WC; Lin, PY; Ou, TT; Wang, CY; Wang, J; Wen, MC, 2010) |
| "Cilostazol was administered (27 or 9 mg kg(-1)d(-1)) to streptozotocin (STZ)-induced diabetic rats for eight weeks." | 1.35 | Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. ( Cao, M; Cheng, L; Gao, L; Guo, R; Hu, J; Li, M; Wang, F; Zhang, T; Zhang, X; Zhao, J, 2008) |
| "We evaluated association between hyperinsulinemia/insulin resistance and microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rat." | 1.32 | Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat. ( Oshiro, Y; Shimabukuro, M; Shimajiri, Y; Takasu, N; Tohma, T; Yamakawa, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SK | 1 |
| Kim, G | 1 |
| Choi, BH | 1 |
| Ryu, D | 1 |
| Ku, SK | 1 |
| Kwak, MK | 1 |
| Daimon, S | 1 |
| Jiao, XM | 1 |
| Jiao, XJ | 1 |
| Zhang, XG | 1 |
| Xu, XP | 1 |
| Wu, JX | 1 |
| Yao, L | 1 |
| Zhao, J | 2 |
| Lü, XF | 1 |
| Asal, NJ | 1 |
| Wojciak, KA | 1 |
| Wang, F | 1 |
| Li, M | 1 |
| Cheng, L | 1 |
| Zhang, T | 1 |
| Hu, J | 1 |
| Cao, M | 1 |
| Guo, R | 1 |
| Gao, L | 1 |
| Zhang, X | 1 |
| Lee, WC | 1 |
| Chen, HC | 1 |
| Wang, CY | 1 |
| Lin, PY | 1 |
| Ou, TT | 1 |
| Chen, CC | 1 |
| Wen, MC | 1 |
| Wang, J | 1 |
| Lee, HJ | 1 |
| Tohma, T | 1 |
| Shimabukuro, M | 1 |
| Oshiro, Y | 1 |
| Yamakawa, M | 1 |
| Shimajiri, Y | 1 |
| Takasu, N | 1 |
| Rosa, MP | 1 |
| Baroni, GV | 1 |
| Portal, VL | 1 |
| Omoto, S | 2 |
| Nomura, S | 1 |
| Shouzu, A | 2 |
| Hayakawa, T | 2 |
| Shimizu, H | 2 |
| Miyake, Y | 2 |
| Yonemoto, T | 1 |
| Nishikawa, M | 2 |
| Fukuhara, S | 1 |
| Inada, M | 2 |
2 reviews available for cilostazol and Diabetic Nephropathies
| Article | Year |
|---|---|
Effect of cilostazol in treating diabetes-associated microvascular complications.
Topics: Cilostazol; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Humans; Tetrazoles | 2017 |
[Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol].
Topics: Cilostazol; Diabetic Nephropathies; Fibrinolytic Agents; Humans; Phosphodiesterase Inhibitors; Plate | 2007 |
2 trials available for cilostazol and Diabetic Nephropathies
| Article | Year |
|---|---|
Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy.
Topics: Albuminuria; Cilostazol; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Tetrazoles | 2013 |
Effects of beraprost and cilostazol and renal function on serum thrombomodulin levels in diabetic patients.
Topics: Cilostazol; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Epoprostenol; Humans; Kidney Func | 2000 |
6 other studies available for cilostazol and Diabetic Nephropathies
| Article | Year |
|---|---|
Negative correlation of urinary miR-199a-3p level with ameliorating effects of sarpogrelate and cilostazol in hypertensive diabetic nephropathy.
Topics: Animals; Biomarkers, Pharmacological; Cilostazol; Diabetic Nephropathies; Disease Models, Animal; Hy | 2021 |
Adverse Effect of Antithrombotic Medications on Bleeding Events and Comparison of Antithrombotic Agents in Hemodialysis Patients.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diabetic Nephropathies; Drug Monitoring; Female; Fibrinolyti | 2019 |
Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemokine CCL2; Cilostazol; Diabetes Mellitus, Exp | 2008 |
Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB.
Topics: Animals; Blood Glucose; Body Weight; Cilostazol; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nep | 2010 |
Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat.
Topics: Albuminuria; Animals; Blood Glucose; Cilostazol; Collagen Type I; Diabetic Nephropathies; Fibronecti | 2004 |
Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy.
Topics: Antigens, CD; Blood Coagulation; Blood Platelets; Case-Control Studies; Cilostazol; Diabetic Nephrop | 1999 |